Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Grifols, a Spanish producer of plasma protein therapies, has agreed to acquire U.S.-based Talecris for about $3.4 billion. Talecris, a former Bayer business that also develops therapies from blood plasma, has been an acquisition candidate since June 2009, when the Federal Trade Commission blocked Australian plasma protein firm CSL from buying it for $3.1 billion. If this deal is approved, it will result in a company with about $2.8 billion in annual sales.
This article has been sent to the following recipient: